Document Type : Original Article


1 Assistant Professor, Department of Neurology, Tohid Hospital, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

2 Resident of Neurosurgery, Students Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran

3 Assistant Professor, Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

4 PhD Student of Health Education & Health Promotion, Students Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran


Background and aims: The most common cause of acute flaccid paralysis of all ages is Guillain-Barre
syndrome (GBS). Further understanding of this disease is important because of its life-threatening
nature in life. The aim of this study was to conduct a 10-year survey on epidemiological and clinical
features of GBS in Tohid and Besat hospitals, Sanandaj, Iran, from 2005 to 2014.
Methods: This study was a retrospective study, based on medical records, in which 98 hospitalized
cases in Tohid and Besat hospitals (tertiary referral hospitals), Sanandaj, Iran, between 2005 and 2014
were investigated. The epidemiological and clinical information was obtained from eligible cases.
Data analysis was performed using SPSS version 16. Chi-square and t test were used for analyses. The
significant level was considered at P < 0.05.
Results: The mean age of cases with GBS was 22.16 years. Among final 69 patients who were studied,
36 cases (52.2%) were male and 33 cases (47.8%) were female. Most cases of disease occurred in
the spring. Thirty-nine patients (56.52%) had risk factors like history of gastrointestinal infections,
respiratory infections, and surgery 2-4 weeks before the disease onset. Four cases (10.25%) needed
mechanical ventilation. The most common protocol of treatment was IVIg (n = 47, 68%). More than
half of the patients (52.2%) achieved relative recovery. In 6 patients, (8.7%) relapse was occurred.
Conclusion: Our study showed that there was a significant relationship between sensory- motor
involvement, gender and age. Moreover, the relationship between gender and prognosis was indicated
(P < 0.05).


1.Mantay KM, Armeau E, Parish T. Recognizing Guillain-Barre Syndrome in the Primary Care Setting. Internet J Allied Health Sci Pract. 2007;5(1):5. 
2.Victor M, Ropper AH. Adams and Victor’s Principle of Neurology. 7th ed. New York: McGraw-Hill; 2001.
3.Burns TM. Guillain-Barre syndrome. Semin Neurol. 2008;28(2):152-67. doi: 10.1055/s-2008-1062261. 
4.Sladky JT. Guillain-Barre syndrome in children. J Child Neurol. 2004;19(3):191-200. 
5.Akbayram S, Dogan M, Akgun C, Peker E, Sayiotan R, Aktar F, et al. Clinical features and prognosis with Guillain-Barre syndrome. Ann Indian Acad Neurol. 2011;14(2):98-102. doi: 10.4103/0972-2327.82793. 
6.Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran. BMC Neurol. 2007;7:22. doi: 10.1186/1471-2377-7-22. 
7.Hauser SL, Asbury AK. Guillain-Barre Syndrome & Other Immune-Mediated Neuropathies.16th ed. In: Harrison’s Principles of Internal Medicine. New York: McGraw Hill 2009. 
8.Amato AA. Guillain-Barre syndrome and related disorders. Rev Mex Neuroci. 2005;6(5):455-69. 
9.Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barre syndrome in children. Pediatr Neurol. 2003;28(4):295-9. doi: 10.1016/ S0887-8994(02)00626-4. 
10.Esteghamati A, Keshtkar A, Gooya M, Zahraee M, Dadras M, Moosavi T. Relationship between Occurrence of GuillanBarre Syndrome and Mass Campaign of Measles and Rubella Immunization in Iranian 5-14 Years Old Children. Iran J Pediatr. 2007;17(Suppl 2):217-23. 
11.Ashrafzadeh F, Ariamanesh A. Outcome of Guillain-Barre syndrome in children. Iran J Pediatr. 2005;15(4):309-14. 
12.McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-63. doi: 10.1159/000184748.
13.Nikkhah K, Etemad Z, Azarpazhoh MR. The effect of intravenous immunoglobulin in improvement of patients with Guillain-Barre Syndrome. Journal of Birjand University of Medical Sciences. 1999;6(1):25-31. [Persian]. 
14.Mazaheri S, Rezaie AA, Hossein Zadeh A. The Ten Years Survey on Clinical and Epidemiologic Features of Guillain-Barre Syndrome in Sina Hospital, Hamadan, Iran. Scientific Journal of Hamadan University of Medical Sciences. 2007;14(2):56- 60. [Persian]. 
15.Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27 Suppl:S21-4. doi: 10.1002/ana.410270707. 
16.Safari A, Borhani-Haghighi A, Heydari ST, Lankarani KB. Increased Guillain-Barre syndrome admissions in Shiraz, southern Iran. Iran J Neurol. 2013;12(1):15-8. 
17.Savadi D, Hashemilor M, Amini N. The survey of clinical and paraclinical characteristics of patients with the GuillainBarre Syndrome hospitalized in Alavi & Ali Asghar Hospitals, Ardabil, Iran (from 2001 to 2005). Ardabil University of Medical Sciences; 2005. 
18.Yoshikawa H. [Epidemiology of Guillain-Barre Syndrome]. Brain Nerve. 2015;67(11):1305-11. doi: 10.11477/ mf.1416200300. 
19.Amin R, Al-Yaseen S, Rafie SM. Guillain Barre Syndrome: a 20-year study on pediatrics. Feyz Journal of Kashan University of Medical Sciences. 2005;8(4):63-8. [Persian]. 
20.Sharma G, Sood S, Sharma S. Seasonal, Age & Gender Variation of Guillain Barre Syndrome in a Tertiary Referral Center in India. Neurosci Med. 2013;4(1):23-8. doi: 10.4236/ nm.2013.41004. 
21.Rocha MS, Brucki SM, Carvalho AA, Lima UW. Epidemiologic features of Guillain-Barre syndrome in Sao Paulo, Brazil. Arq Neuropsiquiatr. 2004;62(1):33-7. doi: 10.1590/S0004- 282X2004000100006. 
22.Huang WC, Lu CL, Chen SC. A 15-Year Nationwide Epidemiological Analysis of Guillain-Barre Syndrome in Taiwan. Neuroepidemiology. 2015;44(4):249-54. doi: 10.1159/000430917. 
23.Nelson L, Gormley R, Riddle MS, Tribble DR, Porter CK. The epidemiology of Guillain-Barre Syndrome in U.S. military personnel: a case-control study. BMC Res Notes. 2009;2:171. doi: 10.1186/1756-0500-2-171. 
24.Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653-66. doi: 10.1016/s0140- 6736(05)67665-9. 
25.Schottlender JG, Lombardi D, Toledo A, Otero C, Mazia C, Menga G. [Respiratory failure in the Guillain Barre syndrome]. Medicina (B Aires). 1999;59(6):705-9. 26. Van Der Mach FG, Van Doorn PA. Guillain Barre syndrome. Curr Treat Option Neurol. 2000;2(6):507-16. 
27.Govoni V, Granieri E. Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol. 2001;14(5):605-13. 
28.Yazdchi M, Mikaeily H, Arami MA, Najmi S, Mansorpoor L. Mortality of guillain-barre syndrome in intensive care unite. Tabib-E-Shargh. 2006;7(4):289-96. [Persian]. 
29.Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wijdicks EF. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology. 2003;60(1):17- 21. doi: 10.1212/01.wnl.0000035640.84053.5b. 
30.Roodbol J, de Wit MY, van den Berg B, Kahlmann V, Drenthen J, Catsman-Berrevoets CE, et al. Diagnosis of Guillain-Barre syndrome in children and validation of the Brighton criteria. J Neurol. 2017;264(5):856-61. doi: 10.1007/s00415-017- 8429-8. 
31.Sudulagunta SR, Sodalagunta MB, Sepehrar M, Khorram H, Bangalore Raja SK, Kothandapani S, et al. Guillain-Barre syndrome: clinical profile and management. Ger Med Sci. 2015;13:Doc16. doi: 10.3205/000220. 
32.Taylor CJ, Hirsch NP, Kullmann DM, Howard RS. Changes in the severity and subtype of Guillain-Barre syndrome admitted to a specialist Neuromedical ICU over a 25 year period. J Neurol. 2017;264(3):564-9. doi: 10.1007/s00415-016- 8380-0.